Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Rubenstein

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Dermatology and Therapy|December 20, 2023
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque PsoriasisLeon Kircik, Matthew Zirwas, Shawn G Kwatra, et al.
Dermatology and Therapy|January 8, 2025
Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and ChildrenEric L Simpson, Adelaide A Hebert, John Browning, et al.
The Journal of Dermatological Treatment|January 12, 2025
Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trialsLinda Stein Gold, James Del Rosso, Benjamin D Ehst, et al.
The Journal of Allergy and Clinical Immunology|December 28, 2023
Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical reviewJonathan I Silverberg, Mark Boguniewicz, Francisco J Quintana, et al.
Dermatology and Therapy|July 22, 2025
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical TrialsAndrew F Alexis, Leon Kircik, Raj Chovatiya, et al.
Journal of the American Academy of Dermatology|June 30, 2022
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trialBruce Strober, Linda Stein Gold, Robert Bissonnette, et al.
Dermatology and Therapy|September 11, 2023
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 TrialsSeemal R Desai, Linda Stein Gold, Michael C Cameron, et al.
Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Dermatology and Therapy|December 20, 2023
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque PsoriasisLeon Kircik, Matthew Zirwas, Shawn G Kwatra, et al.
Dermatology and Therapy|January 8, 2025
Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and ChildrenEric L Simpson, Adelaide A Hebert, John Browning, et al.
The Journal of Dermatological Treatment|January 12, 2025
Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trialsLinda Stein Gold, James Del Rosso, Benjamin D Ehst, et al.
The Journal of Allergy and Clinical Immunology|December 28, 2023
Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical reviewJonathan I Silverberg, Mark Boguniewicz, Francisco J Quintana, et al.
Dermatology and Therapy|July 22, 2025
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical TrialsAndrew F Alexis, Leon Kircik, Raj Chovatiya, et al.
Journal of the American Academy of Dermatology|June 30, 2022
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trialBruce Strober, Linda Stein Gold, Robert Bissonnette, et al.
Dermatology and Therapy|September 11, 2023
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 TrialsSeemal R Desai, Linda Stein Gold, Michael C Cameron, et al.
Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
Pageof 6